EUVIMEDEUVIMED entdecken
VergleichsstudieKohortenstudieOpen Access · CC BY 4.0

Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study

Nao Suzuki, Nobuhiro Ooba iD, Rie Nakajima, Kasumi Takabatake, Masahiro Saita, Eiji Kawakami, Michiyo Kawana, Daiki Watanabe, Hajime Hashiba

PLOS One · 2026

DOI: 10.1371/journal.pone.0359960 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift PLOS One, 2026. Verfasst von Nao Suzuki und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan. Hauptthemen laut MEDLINE: Sitagliptin Phosphate, Diabetes Mellitus, Type 2, Hypoglycemic Agents. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Pharmaceutical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clinical evidence supports the safety and efficacy of imeglimin, a new oral antidiabetic medication that increases insulin secretion and reduces insulin resistance. However, comparative real-world safety data with dipeptidyl peptidase-4 inhibitors, widely used in Japan, remain limited. This retrospective, pharmacy-based cohort study compared the incidence of adverse events (gastrointestinal events and hypoglycemia) among patients newly prescribed imeglimin or sitagliptin in real-world settings. Using a new-user design, we analyzed the 2022–2024 community pharmacy data across Japan, including 1,140 and 990 new imeglimin and sitagliptin users, respectively. Primary outcome (incidence of treatment-related events classified using Medical Dictionary for Regulatory Activities terminology) was evaluated using Cox proportional hazards models. Unadjusted and multivariable-adjusted hazard ratios (aHRs) for events during a 4-month follow-up were estimated. At least one adverse event was reported among 31% of imeglimin users versus 22% of sitagliptin users. Hypoglycemia risk differed non-significantly between groups (aHR: 0.66; 95% confidence interval [CI]: 0.20–2.22). However, imeglimin was associated with substantially higher risks of gastrointestinal events than sitagliptin (aHR: 5.44; 95% CI: 3.44–8.61), particularly nausea (aHR: 15.34; 95% CI: 3.50–67.23), diarrhea (aHR: 7.90; 95% CI: 2.54–24.62), and abdominal discomfort (aHR: 6.02; 95% CI: 1.47–24.58). Sensitivity analyses in patients receiving monotherapy yielded increased risk (hazard ratio (HR): 5.36; 95% CI: 2.63–10.92). Imeglimin use was associated with a higher incidence of gastrointestinal events than sitagliptin in Japanese clinical practice, closely approaching our prespecified threshold for clinical significance. Conversely, no significant difference was observed in hypoglycemia risk, although this finding should be interpreted with caution owing to the limited number of events. Involving community pharmacists allowed for active monitoring and identification of events that are often underreported in large-scale claims databases. Clinicians should prioritize gastrointestinal monitoring during initial stages of imeglimin therapy, particularly in older patients with complex treatment regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sitagliptin PhosphateDiabetes Mellitus, Type 2Hypoglycemic AgentsHumansRetrospective StudiesFemaleJapanMaleHypoglycemiaMiddle AgedAgedDipeptidyl-Peptidase IV InhibitorsEast Asian People

Substanzen

Sitagliptin PhosphateHypoglycemic AgentsDipeptidyl-Peptidase IV Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacoepidemiology, Nihon University School of Pharmacy, Funabashi, Chiba, Japan.
  • Department of Pharmacy Practice in Primary Care, Nihon University School of Pharmacy, Funabashi, Chiba, Japan.
  • Japan Pharmaceutical Association, Shinjuku-ku, Tokyo, Japan.
  • Department of Pharmaceutical Sciences, Teikyo University School of Pharmacy, Itabashi-ku, Tokyo, Japan.

ORCID-Profile: Nobuhiro Ooba

Förderung

  • Japan Pharmaceutical Association

Zitieren

APA

Suzuki, N., Ooba, N., Nakajima, R., Takabatake, K., Saita, M., Kawakami, E., Kawana, M., Watanabe, D., & Hashiba, H. (2026). Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study. PLOS One. https://doi.org/10.1371/journal.pone.0359960

Vancouver

Suzuki N, Ooba N, Nakajima R, Takabatake K, Saita M, Kawakami E, et al. Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study. PLOS One. 2026. doi:10.1371/journal.pone.0359960

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Nao and Ooba, Nobuhiro and Nakajima, Rie and Takabatake, Kasumi and Saita, Masahiro and Kawakami, Eiji and Kawana, Michiyo and Watanabe, Daiki and Hashiba, Hajime},
  title = {Comparative safety of imeglimin versus sitagliptin in Japanese patients with type 2 diabetes: A pharmacy-based retrospective cohort study},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0359960}
}
Kostenlos starten →